AXA Framlington Biotech fund Acc
(MUTF_GB:GB0031007254) Watch this mutual fundFind more results for
Axa Framlington Biotech fund
Performance
Trailing returns
| Best 3 month return | +35.26% | |
| Worst 3 month return | -35.83% |
Morningstar statistics
Morningstar category: Sector Equity Biotechnology
| Return | Risk | Rating | |
| 3 years | - | - |
 
|
| 5 years | - | - |
|
| 10 years | - | - | - |
| Overall | - | - |
|
Morningstar style Learn more
| Large | |||
| Mid | |||
| Small | |||
| Value | Blend | Growth |
Key statistics
| Total assets | ||
| Front load | 5.50% | |
| Deferred load | - | |
| Expense ratio | - | |
| Management fee | 1.75% | |
| Fund family | AXA Framlington Unit Management Limited |
Asset allocation
| Cash | 0.78% | |
| Stocks | 99.21% | |
| Bonds | 0.00% | |
| Other | 0.00% |
Purchase information
| Initial | UK£1,000 | |
| Additional | UK£100 | |
| AIP Initial | UK£50 | |
| AIP Additional | UK£50 |
0.00
0.00 (0.00%)
Feb 1, 4:00PM GMT
Overall Morningstar RatingTM
Description
To provide long term capital growth by investing principally in companies in the biotechnology, genomic and medical research industries worldwide. The fund invests in around 90-100 companies.
Asset manager:
Deane Donnigan (Started: Feb 27, 2007)
Deane Donnigan (Started: Feb 27, 2007)
Advisor Company:
AXA Framlington Investment Mgmt Ltd
AXA Framlington Investment Mgmt Ltd
Risk
| 1 year | 3 years | 5 years | 10 years | ||
| Alpha* | -2.88 | -5.93 | -5.62 | - | |
| Beta* | 0.88 | 0.73 | 0.72 | - | |
| Mean annual return | -0.44 | -0.24 | 0.03 | - | |
| R-squared* | 76.75 | 47.30 | 39.23 | - | |
| Standard deviation | 25.00 | 19.60 | 20.72 | - | |
| Sharpe ratio | -0.24 | -0.31 | -0.14 | - | |
| * Against standard index | |||||
Top 10 holdings
| Security | Net Assets | |
| Gilead Sciences, Inc. (GILD) | 9.91% | |
| Celgene Corporation (CELG) | 8.01% | |
| Amgen, Inc. (AMGN) | 5.09% | |
| Genentech, Inc. (DNA) | 5.05% | |
| CSL Limited (CSL) | 4.72% | |
| Cypress Biosciences, Inc. (CYPB) | 4.30% | |
| MorphoSys AG (MOR) | 3.76% | |
| Alexion Pharmaceuticals, Inc. (ALXN) | 3.42% | |
| Isis Pharmaceuticals (ISIS) | 3.27% | |
| Affymax, Inc. (AFFY) | 3.23% |